Researchers from the California NanoSystems Institute (CNSI) at the University of California, Los Angeles, have developed a patented technology that can inhibit and prevent the growth of pancreatic cancer in the liver. The technology’s goal is to reprogram the liver’s immune defense to attack pancreatic cancer. Key to this technology are liver-targeting nanoparticles that deliver two key components: an mRNA vaccine targeting an immune-activating marker commonly found in pancreatic cancer, and a small molecule that boosts the immune response. “This technology could potentially change the course of metastatic pancreatic cancer, as well as preventing spread to the liver in newly diagnosed patients without metastases,” said André Nel, one of the scientists involved in this study.
An official website of the United States government.
